NASDAQ:VRCA - Verrica Pharmaceuticals Stock Price, News & Analysis

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) posted its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.28) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.02. View Verrica Pharmaceuticals' Earnings History.

Verrica Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Verrica Pharmaceuticals.

1 equities research analysts have issued twelve-month price objectives for Verrica Pharmaceuticals' stock. Their predictions range from $23.00 to $23.00. On average, they expect Verrica Pharmaceuticals' stock price to reach $23.00 in the next year. This suggests a possible upside of 165.9% from the stock's current price. View Analyst Price Targets for Verrica Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verrica Pharmaceuticals.

Press coverage about VRCA stock has been trending positive on Sunday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a news impact score of 2.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Verrica Pharmaceuticals.

Verrica Pharmaceuticals saw a drop in short interest in July. As of July 15th, there was short interest totalling 606,200 shares, a drop of 16.3% from the June 15th total of 724,400 shares. Based on an average trading volume of 50,300 shares, the days-to-cover ratio is currently 12.1 days. Currently, 5.0% of the shares of the stock are short sold. View Verrica Pharmaceuticals' Current Options Chain.

Some companies that are related to Verrica Pharmaceuticals include Y-mAbs Therapeutics (YMAB), Spectrum Pharmaceuticals (SPPI), ZIOPHARM Oncology (ZIOP), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), Emisphere Technologies (EMIS), Principia Biopharma (PRNB), Homology Medicines (FIXX), Arvinas (ARVN), Akero Therapeutics (AKRO), ANI Pharmaceuticals (ANIP), Amneal Pharmaceuticals (AMRX), Eagle Pharmaceuticals (EGRX), Cytokinetics (CYTK) and Vanda Pharmaceuticals (VNDA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include Johnson & Johnson (JNJ), Thermo Fisher Scientific (TMO), Amgen (AMGN), Home Depot (HD), Honeywell International (HON), Raytheon (RTN), Verizon Communications (VZ), Cisco Systems (CSCO), CSX (CSX) and Texas Instruments (TXN).

(VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

Verrica Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.46%), Kornitzer Capital Management Inc. KS (1.88%), Vanguard Group Inc. (1.78%), Point72 Asset Management L.P. (0.55%), Asymmetry Capital Management L.P. (0.52%) and Northern Trust Corp (0.43%). Company insiders that own Verrica Pharmaceuticals stock include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White. View Institutional Ownership Trends for Verrica Pharmaceuticals.

VRCA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P.. View Insider Buying and Selling for Verrica Pharmaceuticals.

VRCA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Asymmetry Capital Management L.P., Kornitzer Capital Management Inc. KS, Vanguard Group Inc., Wells Fargo & Company MN, Bank of America Corp DE, Bank of New York Mellon Corp and Northern Trust Corp. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning, Sean Stalfort and Ted White. View Insider Buying and Selling for Verrica Pharmaceuticals.

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of VRCA stock can currently be purchased for approximately $8.65.

Verrica Pharmaceuticals has a market capitalization of $222.65 million. The company earns $-20,650,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.View Additional Information About Verrica Pharmaceuticals.

The official website for Verrica Pharmaceuticals is http://www.verrica.com/.

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]